Value of CEA determination in biological fluids and tissues

Discrimination of exudative pleural effusions based on multiple biological parameters

“…CEA was one of the first markers to be evaluated in lung cancer [24]. Determination of CEA concentration can be used as a diagnostic tool for MPE since 40-70% of pleural fluids give positive CEA assay results [25]. In accordance with previous reports, CEA was found to be the best single tumour marker in pleural fluid [26,27].…”

Discrimination of exudative pleural effusions based on multiple biological parameters

“…CEA was one of the first markers to be evaluated in lung cancer [24]. Determination of CEA concentration can be used as a diagnostic tool for MPE since 40-70% of pleural fluids give positive CEA assay results [25]. In accordance with previous reports, CEA was found to be the best single tumour marker in pleural fluid [26,27].…”

The Carcinoembryonic Antigen (CEA): Past, Present, and Future

“…In lung cancer, CEA can also be a useful biomarker. CEA is elevated in approximately two-thirds of nonsmall cell lung cancer patients and one-third of those with small cell lung cancer (134)(135)(136). Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases.…”

“…Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases. Determination of CEA concentration can be used as a diagnostic tool for malignant pleural effusions, in that 40-70% of the fluids from initial pleural taps give positive CEA assays (136). However, although no large randomized study has been performed to date, preliminary work has suggested limited clinical utility for serum CEA and BALF CEA in the diagnosis of lung cancer (137).…”

Enhanced Expression of Aggrus (T1alpha/Podoplanin), a Platelet-Aggregation-Inducing Factor in Lung Squamous Cell Carcinoma

“…Therefore, the availability of a reliable tumor marker that would refl ect the change in tumor burden would be helpful to: specify treatment protocols; determine which patients need more aggressive surgery, adjuvant chemotherapy, or radiotherapy; monitor treatment effi cacy, and to assist in decision-making for further therapy in NSCLCs. For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] .…”

“…For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] . Sensitivity of CYFRA21-1, which seems to have the highest sensitivity in squamous cell carcinoma of lung thus far, is 57% for squamous cell carcinoma and 27% for adenocarcinoma of the lung [24] , whereas those of Aggrus are 67 and 0%, respectively, when the cutoff values of the T/N ratio were defi ned as 1.5 in Cancer Profi ling Array.…”

Discrimination of exudative pleural effusions based on multiple biological parameters

“…CEA was one of the first markers to be evaluated in lung cancer [24]. Determination of CEA concentration can be used as a diagnostic tool for MPE since 40-70% of pleural fluids give positive CEA assay results [25]. In accordance with previous reports, CEA was found to be the best single tumour marker in pleural fluid [26,27].…”

The Carcinoembryonic Antigen (CEA): Past, Present, and Future

“…In lung cancer, CEA can also be a useful biomarker. CEA is elevated in approximately two-thirds of nonsmall cell lung cancer patients and one-third of those with small cell lung cancer (134)(135)(136). Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases.…”

“…Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases. Determination of CEA concentration can be used as a diagnostic tool for malignant pleural effusions, in that 40-70% of the fluids from initial pleural taps give positive CEA assays (136). However, although no large randomized study has been performed to date, preliminary work has suggested limited clinical utility for serum CEA and BALF CEA in the diagnosis of lung cancer (137).…”

Enhanced Expression of Aggrus (T1alpha/Podoplanin), a Platelet-Aggregation-Inducing Factor in Lung Squamous Cell Carcinoma

“…Therefore, the availability of a reliable tumor marker that would refl ect the change in tumor burden would be helpful to: specify treatment protocols; determine which patients need more aggressive surgery, adjuvant chemotherapy, or radiotherapy; monitor treatment effi cacy, and to assist in decision-making for further therapy in NSCLCs. For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] .…”

“…For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] . Sensitivity of CYFRA21-1, which seems to have the highest sensitivity in squamous cell carcinoma of lung thus far, is 57% for squamous cell carcinoma and 27% for adenocarcinoma of the lung [24] , whereas those of Aggrus are 67 and 0%, respectively, when the cutoff values of the T/N ratio were defi ned as 1.5 in Cancer Profi ling Array.…”

Discrimination of exudative pleural effusions based on multiple biological parameters

“…CEA was one of the first markers to be evaluated in lung cancer [24]. Determination of CEA concentration can be used as a diagnostic tool for MPE since 40-70% of pleural fluids give positive CEA assay results [25]. In accordance with previous reports, CEA was found to be the best single tumour marker in pleural fluid [26,27].…”

The Carcinoembryonic Antigen (CEA): Past, Present, and Future

“…In lung cancer, CEA can also be a useful biomarker. CEA is elevated in approximately two-thirds of nonsmall cell lung cancer patients and one-third of those with small cell lung cancer (134)(135)(136). Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases.…”

“…Both the frequency and levels of CEA elevation are considerably lower in patients with benign lung diseases. Determination of CEA concentration can be used as a diagnostic tool for malignant pleural effusions, in that 40-70% of the fluids from initial pleural taps give positive CEA assays (136). However, although no large randomized study has been performed to date, preliminary work has suggested limited clinical utility for serum CEA and BALF CEA in the diagnosis of lung cancer (137).…”

Enhanced Expression of Aggrus (T1alpha/Podoplanin), a Platelet-Aggregation-Inducing Factor in Lung Squamous Cell Carcinoma

“…Therefore, the availability of a reliable tumor marker that would refl ect the change in tumor burden would be helpful to: specify treatment protocols; determine which patients need more aggressive surgery, adjuvant chemotherapy, or radiotherapy; monitor treatment effi cacy, and to assist in decision-making for further therapy in NSCLCs. For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] .…”

“…For the detection of changes in tumor behavior of NSCLCs, several tumor markers have been evaluated, including carcinoembryonic antigen, squamous cell carcinoma antigen and soluble cytokeratin 19 fragment (CYFRA21-1) [22][23][24] . Some study results have revealed that these markers may contribute to diagnosis, staging, monitoring, and prognosis of NSCLCs to some extent, but that they are not yet ideal, especially in squamous cell carcinoma [22][23][24] . Sensitivity of CYFRA21-1, which seems to have the highest sensitivity in squamous cell carcinoma of lung thus far, is 57% for squamous cell carcinoma and 27% for adenocarcinoma of the lung [24] , whereas those of Aggrus are 67 and 0%, respectively, when the cutoff values of the T/N ratio were defi ned as 1.5 in Cancer Profi ling Array.…”